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The differentiation of CD4+ helper T cell subsets with
diverseeffector functions isaccompaniedbychanges
in metabolism required to meet their bioenergetic de-
mands. We find that follicular B helper T (Tfh) cells
exhibited less proliferation, glycolysis, andmitochon-
drial respiration, accompanied by reduced mTOR ki-
nase activity compared to T helper 1 (Th1) cells in
response to acute viral infection. IL-2-mediated acti-
vation of the Akt kinase and mTORc1 signaling was
both necessary and sufficient to shift differentiation
away from Tfh cells, instead promoting that of Th1
cells. Thesefindingswerenot the result of generalized
signaling attenuation in Tfh cells, because they re-
tained the ability to flux calcium and activate NFAT-
transcription-factor-dependent cytokine production.
These data identify the interleukin-2 (IL-2)-mTORc1
axis as a critical orchestrator of the reciprocal balance
between Tfh and Th1 cell fates and their respective
metabolic activities after acute viral infection.
INTRODUCTION
The differentiation of functionally distinct CD4+ T helper (Th) cell
subsets from naive precursors occurs through the concerted ac-
tions of cognate peptide:major histocompatibility complex class
II (MHCII) molecular interactions, co-stimulation, and polarizing
cytokine signals. Follicular B helper T (Tfh) cells are distinguished
from other Th cells by their selective role in initiating and orches-
trating germinal center (GC) responses, with promotion of immu-
noglobulin affinitymaturation and development ofmemory B and
long-lived plasma cells (Crotty, 2011).
Differential cytokine signaling regulates Tfh versus Th1 cell dif-
ferentiation. Interleukin-6 (IL-6) and autocrine IL-21 signaling via
the STAT3 transcription factor potentiates Bcl6 upregulation and
differentiation of Tfh cells (Eto et al., 2011; Karnowski et al., 2012;
Linterman et al., 2010; Nurieva et al., 2008; Ray et al., 2014),690 Immunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc.whereas IL-2 activation of STAT5 suppresses STAT3 binding
to the Bcl6 locus and promotes the expression of the transcrip-
tion factor PR domain zinc finger protein 1 (B lymphocyte-
induced maturation protein-1 [Blimp-1]), necessary for Th1 cell
differentiation (Johnston et al., 2012; Oestreich et al., 2012).
The expression of Bcl6 and Blimp-1 are mutually exclusive,
with overexpression of either sufficient to drive the differentiation
of Tfh or Th1 cells, respectively, at the expense of the other
(Johnston et al., 2009). Tfh cells accordingly have reduced inter-
leukin-2 receptor a chain (IL-2Ra, CD25) expression and p-
STAT5 signaling, and as a result, reduced Blimp-1 synthesis,
enabling their Bcl6-dependent differentiation (Choi et al., 2013;
Ray et al., 2014).
IL-2 induction of Blimp-1 through p-STAT5 is important for
Th1 cell differentiation, but this cytokine also signals via
phosphatidylinositol-3-OH kinase (PI3K), the serine-threonine
kinase Akt, and the nutrient sensor and metabolic regulator
mTOR (Powell et al., 2012). CD28 also is an inducer of PI3K,
as well as IL-2 production, during T cell priming (Harada
et al., 2003). Thus, T cell co-stimulation and IL-2 jointly feed
into the PI3K pathway, enabling effector T cells to activate
mTOR, with the latter promoting cellular growth, nutrient up-
take, protein synthesis, and clonal expansion (Brennan et al.,
1997; Sinclair et al., 2013). Th1, Th2, and Th17 cells depend
on mTOR signaling to varying degrees to guide their expres-
sion of lineage-defining transcription factors—T-bet, GATA3,
and RORgt, respectively—and to carry out their specialized
effector functions (Delgoffe et al., 2009; Powell et al., 2012).
In contrast, the differentiation of regulatory T (Treg) and mem-
ory CD8+ T cells is fostered by attenuated mTOR activity (Del-
goffe et al., 2009; Michalek et al., 2011) and a reliance on fatty
acid oxidation (O’Sullivan et al., 2014; Pearce et al., 2009; van
der Windt et al., 2012).
Because Tfh cell differentiation requires reduced IL-2 and
STAT5 signaling, these cells are likely to exhibit reduced mTOR
activity (Johnston et al., 2012). This idea finds support in the
observation that the expression of T-bet and granzymes, which
are dependent on IL-2 and mTOR signaling in CD4+ and CD8+
T cells (Delgoffe et al., 2009; Rao et al., 2010), is reduced in Tfh
cells. Additionally, Bcl6 has recently been reported to downre-
gulate genes associated with glycolysis, with T-bet conversely
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Figure 1. Tfh Cells Are Less Proliferative than Th1 Cells
(A) Cell cycle gene signature of differentially expressed transcripts in Tfh and Th1 cells. Genes selected according to DAVID analysis. Transcripts of cyclins,
cyclin-dependent kinases, and elongase factors are listed.
(B) Ki67 staining at 8 dpi of LCMV.
(C) Percentages of Stg+CD4+CD44+PSGL-1lo and Stg+CD4+CD44+PSGL-1hi cells that were apoptotic or at different cell cycle stages, as determined by pro-
pidium iodide (PI) staining.
(D) p-Rb staining in Tfh (Stg+CD4+CD44+Ly6cloPSGL-1lo) and Th1 (Stg+CD4+CD44+Ly6chiPSGL-1hi) cells (Marshall et al., 2011; Ray et al., 2014).
(B and D) Blue and red lines represent gating on Tfh and Th1 cells, respectively, with filled gray histograms denoting naive CD4+ T cells.
Results are representative of two independent experiments with at least four animals per experiment (B, D); data from two independent experiments combined in
(C). Data presented as +SEM (B, D). Student’s unpaired t test (B–D). Please see Figure S1 and Table S1.inhibiting Bcl6-mediated repression of genes involved in its regu-
lation (Oestreich et al., 2014).
Herein, we have used an acute viral model in order to better
understand the role of IL-2 and mTOR signaling in Tfh cell devel-
opment and function. We found that Tfh cells are less prolifera-
tive and have less glycolysis and mitochondrial oxidation than
Th1 cells, results stemming from a paucity in IL-2 signaling and
activation of mTOR through PI3K and Akt. Although Akt and
mTOR signaling in response to IL-2 was essential to promote
Blimp-1 and T-bet expression and differentiation of the Th1
cell lineage, this occurred at the expense of Tfh cells. Despite
the reduction in these signaling cascades, we found that calcium
influx in Tfh cells, nuclear translocation of the transcription factor
nuclear factor of activated T cells (NFAT), and NFAT-mediated
production of the canonical Tfh cell cytokine IL-21 remained
intact, demonstrating that there is a selective defect in Akt and
mTOR signaling in these cells. These findings unveil a linear
pathway of IL-2/Akt-mTOR signaling in regulating the recip-
rocal identity and metabolism of Tfh and Th1 cells after acute
viral infection.
RESULTS
Tfh Cells Are Less Proliferative than Th1Cells after Viral
Challenge
We utilized RNA-seq data (Ray et al., 2014) to better understand
the signaling and metabolic pathways that control the dif-
ferentiation of Tfh cells (sorted on previously defined markers
CD4+CD44+PSGL-1loLy6cloCXCR5hi), with comparison to ter-
minal effector Th1 cells (CD4+CD44+Ly6chiPSGL-1hi) at 8 days
post-lymphocytic choriomeningitis virus (LCMV) infection (dpi)(Marshall et al., 2011; Ray et al., 2014). To parse patterns in
the global gene expression programs of Tfh versus Th1 cells,
we used the DAVID gene ontology website (https://david.
ncifcrf.gov/, Table S1). Among the top differentially expressed
gene sets were those involved in cell cycle regulation, including
cyclins, cyclin-dependent kinases, and elongation factors (Fig-
ures 1A and S1A and Table S1), consistent with a previous report
(Choi et al., 2013). To confirm whether cell-cycle-affiliated pro-
tein expression was reduced in viral-specific Tfh cells compared
to Th1 cells, we transferred 2 3 104 LCMV GP66 SMARTA TCR
transgenic (Stg+) CD4+ T cells into congenically marked wild-
type recipients and infected them with the Armstrong strain of
LCMV (Oxenius et al., 1998). Because expression of Ly6c and
PSGL-1 distinguishes Tfh from Th1 cells and correlates with
the respective cell subsets (Hale et al., 2013; Marshall et al.,
2011), we used them as markers unless otherwise noted in the
figure legend. Staining for the proliferation marker Ki67 was
reduced in Stg+ Tfh cells compared to Stg+ Th1 cells at 8 dpi (Fig-
ure 1B), consistent with the gene expression data.
To determine the stage of the cell cycle in which Tfh cells were
arrested, we used propidium iodide staining to distinguish
apoptosis and the G0/G1, S, and G2 phases of the cell cycle
(Staron et al., 2011). Although Tfh cells were mainly apoptotic
or in the G/0G1 phases at day 5 dpi, Th1 cells were enriched
at the S and G2 phases (Figures 1C and S1B). Tfh cells also
were more robustly stained with caspase and Annexin V
compared to Th1 cells at 8 dpi (Figures S1C and S1D). Analysis
of Tfh cells, designated as CXCR5hi, ICOShi, and/or PD-1hi, repli-
cated these findings (Figures S1E and S1F; data not shown).
Moreover, phosphorylated retinoblastoma tumor suppressor
protein (p-Rb), which allows E2F-driven G1- to S-phase cellImmunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc. 691
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Figure 2. Tfh Cells Have Reduced Metabolic Function Compared to Th1 Cells
(A) Mitotracker Deep Red (DR)/Mitotacker Green ratio of Tfh and Th1 cells at day 5 dpi.
(B) Baseline OCR for Tfh and Th1 cells (left); seahorse traces for oxygen consumption rate (OCR) of Tfh and Th1 cells at 8 dpi, with measurements taken at
baseline (calculated as the average of all three baseline data points) and after treatment with oligomycin, FCCP, etomoxir, and rotenone (right).
(C) 2-NBDG uptake by Tfh and Th1 cells at 5 dpi.
(D) Baseline ECAR (left); seahorse traces for extracellular acidification rate (ECAR) of Tfh and Th1 cells at 8 dpi (right).
(E) Ratio of OCR to ECAR for Tfh and Th1 cells at baseline.
(F–H) OCR, ECAR, and OCR/ECAR ratios of Stg cells after retroviral overexpression of Bcl6, compared to control vector (MIGR1).
Blue and red lines represent gating on Tfh and Th1 cells, respectively, with the filled gray histogram (C) denoting naive CD4+ T cells. Results (B–D) are repre-
sentative of two to three independent experiments with three to five animals per experiment. Student’s unpaired t test (A, B [left panel], C, D [left panel], E–
H). +SEM (A–H). Two-way ANOVA (B and D [right panels]) with multiple comparisons comparing means at each time point. *p% 0.05, **p% 0.01, ****p% 0.0001.
Please see Figure S2.cycle progression, was significantly reduced in Stg+ Tfh com-
pared to Stg+ Th1 cells at 5 dpi (Figure 1D).
Features of Anabolic Metabolism Are Reduced in Tfh
Cells Compared to Th1 Cells
Progression through the cell cycle is accompanied by the upre-
gulation of aerobic glycolytic metabolism that allows for optimal
cell growth and division (Pearce and Pearce, 2013). Tfh cells had
reduced proliferation compared to Th1 cells (Figure 1B), so we
asked whether their metabolic function, particularly their ability
to utilize glycolysis and oxidative phosphorylation, was compar-
atively impaired. The consumption and utilization of glucose in
the presence of oxygen, or aerobic glycolysis, is upregulated in
proliferative effector T cell subsets (Fox et al., 2005; Jones and
Thompson, 2007). Furthermore, aerobic glycolysis as part of
anabolic metabolism is differentially regulated among effector,
regulatory, and memory T cell subsets that have different immu-
nological functions and bioenergetic demands (Dang et al.,
2011; Michalek et al., 2011; Pearce et al., 2009; Shi et al.,
2011). We analyzed the mitochondrial mass and function of Tfh
cells and Th1 cells during their development (5 dpi). Although
these subsets were not different in mitochondrial mass as as-692 Immunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc.sessed by Mitotracker Green labeling, there was a slight reduc-
tion in the mitochondrial membrane potential of Tfh cells, deter-
mined byMitotracker Deep Red (DR) (Figures S2A and S2B). The
ratio of mitochondrial mass to potential in Tfh cells indicated
significantly reduced mitochondrial activity compared to their
Th1 cell counterparts (Figure 2A). Although their baseline oxygen
consumption rate (OCR) was similar to that of Th1 cells, uncou-
pling the mitochondrial proton gradient to allow for maximal
respiratory capacity via FCCP (carbonyl cyanide p-trifluoro-
methoxyphenylhydrazone) revealed a significant reduction in
the maximal respiratory capacity of Tfh cells (Figure 2B, right).
The fluorescent glucose analog 2-NBDG is used to assess
cellular glucose uptake, with 2-NBDGlo CD8+ T cells expressing
more Bcl6 than 2-NBDGhi cells (Sukumar et al., 2013). Consis-
tent with these studies, Tfh cells had reduced 2-NBDG staining
(Figure 2C). And, consistent with this latter finding, Tfh cells
displayed reduced extracellular acidification rates (ECAR), a
measure of glycolysis, at baseline as well as upon blockade of
mitochondrial ATP synthesis by oligomycin, a gauge of glycolytic
flux (Figure 2D). To ensure that this phenomenon was not due
to apoptotic Tfh cells, we baseline corrected the data at mea-
surement 3 (Figure S2C). With this correction, we found that
Tfh cell maximal respiratory capacity was more similar to that of
Th1 cells compared to the non-baseline-corrected condition,
whereas their ability to acidify their extracellular environment re-
mained substantially reduced. Thus, although Tfh cells had over-
all reduced mitochondrial and glucose metabolism, they were
relatively more oxidative than glycolytic compared to Th1 cells,
as demonstrated by an increase in their OCR/ECAR baseline ra-
tio (Figure 2E). Because Bcl6 competes with T-bet to regulate the
glycolytic gene program of T cells (Oestreich et al., 2014), we
overexpressed Bcl6 in vitro, finding that this transcription factor
was able to suppress CD4+ T cell ECAR, recapitulating the
reduction in glucose metabolism and higher reliance on oxida-
tive metabolism that we observed in Tfh compared to Th1 cells
(Figures 2F–2H). In sum, Tfh cells are less glycolytic, and
compared to Th1 cells, they rely more heavily on mitochondrial
function than glycolysis.
Tfh Cells Compared to Th1 Cells also Have Reduced Akt
and mTOR Signaling
The reduced glycolytic metabolism of Tfh compared to Th1 cells
suggested that there might be differences in their integration of
signaling pathways. Our RNA-seq data indicated that Tfh cells
had reduced expression of cell cycle, growth, and metabolism
signaling cascades, including members of the Ras and phos-
phoinositide 3-kinase (PI3K) families (Figures 3A and S1A and
Table S2). Integrated Pathway Analysis (IPA) using the Ingenuity
platform (http://www.ingenuity.com) revealed a pattern of gene
expression in Tfh cells compared to Th1 cells consistent with
inhibition of PI3K and Akt signaling (i.e., reduced Pik3c2b and
Pik3cg) and of factors that can facilitate anabolic metabolism
(i.e., reduced Rps6ka1 and Rps6ka5) (Figure 3A and Table S3).
Although generally regulated post-translationally, there is evi-
dence for transcriptional regulation of these pathways. For
example, PI3K is positively regulated at the transcriptional level
via TNFa and NF-kB signaling in ovarian cancer (Yang et al.,
2008), consistent with the finding that Th1 cells reside in the
proinflammatory splenic red pulp, whereas Tfh cells localize in
white pulp B cell follicles (Marshall et al., 2011). In line with these
data, we found p-Akt308, p-Akt473, the ribosomal protein S6 (p-
S6), and p-FoxO1 and 3a to be reduced in Tfh cells (Figures
3C–3F). Tfh cells were also substantially smaller than Th1 cells
over the course of their development (Figure 3G), with reduced
expression of amino acid receptor CD98 (Figure 3H). Thus, Tfh
cells displayed a reduction in activity of Akt and the nutrient
sensor mTOR compared to Th1 cells (Figure 3B).
NFAT Signaling Is Intact in Tfh Cells
We next examined signaling pathways downstream of the TCR,
observing that Tfh cells had reduced NFAT-affiliated gene tran-
scription (Figure S3A and Table S4). Activation of this family of
transcriptional cofactors with AP-1 and NF-kB, among others,
by calcium influx in response to TCR and costimulatory signals
upregulates the expression of genes involved in T cell priming,
such as Il2 and Cd25 (Hermann-Kleiter and Baier, 2010; Pollizzi
and Powell, 2014). Although the expression of many NFAT-
dependent gene transcripts was reduced in Tfh cells, the Tfh
cell transcriptional profile contained a small subset that were up-
regulated (e.g., Egr2, Egr3, and Rnf128) by this transcription fac-
tor in the absence of cofactors (Figure 4A; Macia´n et al., 2002;Wherry, 2011). This transcriptional profile is consistent with the
activity of NFAT in the absence of that of AP-1, in agreement
with the finding that Tfh cells have reduced AP-1 transcriptional
activity due to Bcl6-AP-1 protein-protein interactions (Hatzi
et al., 2015). Therefore, we asked whether Tfh cells maintained
the ability to flux calcium upon stimulation, finding that they did
so as well as, if not more robustly than, Th1 cells at 8 dpi (Fig-
ure 4B). Using Amnis Imagestream analysis, we also observed
an increase in the nuclear:cytoplasmic ratio of Nfatc1 at baseline
and upon stimulation in Tfh cells compared to Th1 cells (Figures
4C–4E and S3B). Although cyclosporine A (CsA) blocked nuclear
translocation of Nfatc1 in CD4+ T cells, treatment with rapamycin
(RAPA) had little effect (Figures S3C and S3D). To this end,
we examined the ability of Stg+ Tfh cells to produce IL-21 and
IFN-g ex vivo 8 dpi in response to LCMV GP66 stimulation in
the presence of CsA or RAPA. Because we had limited anti-
body-conjugated fluorophore options for staining PSGL-1, we
gated Tfh cells as Stg+CD4+CD44+Ly6cloCXCR5hi and Th1 cells
as Stg+CD4+CD44+Ly6chiCXCR5lo. Although IL-21 and IFN-g
production was essentially ablated by CsA treatment, RAPA
had little effect (Figures 4F and 4G), consistent with the observa-
tion that NFAT is required for IL-21 signaling in vitro (Kim et al.,
2005). We also asked whether Tfh cells require glucose or oxida-
tive phosphorylation to promote cytokine responses using the
glucose analog 2-DG and oligomycin, finding that both bioener-
getic pathwayswere necessary (Figure S3E). These data indicate
that although mTOR activity is inactive in Tfh compared to Th1
cells, calcium signaling with NFAT nuclear translocation is oper-
ational and required for Tfh cell cytokine production. In addition,
both oxidative phosphorylation and glucose uptake are required
for Tfh cell cytokine production, despite mTOR dispensability, in
contrast toTregcellswherebothmTORandglucosearedispens-
able (Delgoffe et al., 2009; Michalek et al., 2011).
Signaling via PI3K, Akt, and mTOR Promotes Th1 Cell
Differentiation at the Expense of that of Tfh Cells
Bcl6 controls the differentiation of Tfh cells, whereas T-bet and
Blimp-1 regulate Th1 cell fate (Johnston et al., 2009; Oestreich
et al., 2011). However, how these transcription factors affect
metabolic properties in T cells is unclear. Our RNA-seq results
confirmed that transcripts of transcription factors associated
with Tfh versus Th1 cell differentiation segregated with their
respective populations (Figure 5A and Table S5). For example,
Prdm1 (Blimp-1) expression was markedly elevated in Th1 cells
compared to Tfh cells, with the latter having relatively higher
expression ofBcl6. Accordingly, we used a Blimp-1 YFP reporter
to segregate these subsets early during their differentiation after
LCMV infection (Rutishauser et al., 2009), asking whether the
reduction in Tfh versus Th1 cell Akt andmTORactivities (Figure 3)
was concordant with the expression of transcription factors
associated with Tfh and Th1 cell fates. As expected, Blimp-1
YFP+CD4+ T cells were enriched in cells of the Th1 cell, but not
Tfh cell, phenotype (Figure 5B). Virtually all Blimp-1 YFP+ cells
were blastogenic, as evidenced by increased FSC-A, and dis-
played increased surface expression of the PI3K-dependent
amino acid receptor CD98 (Figures 5C and 5D). p-S6 was
also enriched in the Blimp-1 YFP+ population in vitro and depen-
dent on PI3K, Akt, and mTOR signaling as determined with
the inhibitors LY294002 (LY), AktI, and RAPA, respectivelyImmunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc. 693
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Figure 3. Tfh Cells Have Reduced Signaling via Metabolic Pathways Compared to Th1 Cells
(A) Signature of differentially expressed signaling-pathway genes in Tfh and Th1 cells. Genes associated with the Ras and PI3K pathways are highlighted.
(B) Th1 cell PI3K signaling pathway (left); components of the Th1 cell pathways that could be inhibited to recapitulate the Tfh cell signaling signature according to
IPA (right). Relative size of the Th1 versus Tfh cell is representative of size determined by flow cytometry (see G).
(C and D) p-Akt308 and p-Akt473 staining, respectively, in Tfh and Th1 cells at 5 dpi.
(E) p-S6 staining of Tfh and Th1 cells at 5 dpi.
(F) p-FoxO1 and 3a staining of Tfh and Th1 cells at 5 dpi.
(G) p-S6 by FSC-A mean fluorescence intensity (MFI) in Tfh and Th1 cells at 5 dpi (left); FSC-A at 3, 5, and 8 dpi of Tfh and Th1 cells (right).
(H) CD98 expression of Tfh and Th1 cells at 5 dpi.
Blue and red lines represent gating on Tfh and Th1 cells, respectively, with the filled gray histograms denoting naive CD4+ T cells (C–H). Results (C–H) are
representative of two independent experiments with five animals per experiment. +SEM (C–H); Student’s unpaired t test (C–F, H). Two-way ANOVA with multiple
comparisons comparing means at each time point (G). **p% 0.01, ****p% 0.0001. Please see Table S2 and Table S3.(Figure 5E; Staron et al., 2014). Furthermore, treatment with LY
and RAPA reduced the ECAR of in vitro activated T cells (Fig-
ure S4A), in line with a role for mTOR in inducing glycolysis in
Blimp-1 YFP+ cells.
TCR and cytokine signaling precedes the upregulation of tran-
scription factors required for T cell subset differentiation. In CD4+
T cells, IL-2 induces Blimp-1 expression at the expense of that of
Bcl6 (Oestreich et al., 2012). Using graded doses of TCRand IL-2,
we confirmed that Blimp-1 YFP was increased by TCR signaling694 Immunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc.and IL-2, with the latter effectively lowering the threshold of such
expression (Figure 5F, left). Although Blimp-1 YFP expression
was almost entirely PI3K, Akt, and mTOR dependent, as deter-
mined by inhibition of their respective signaling (Figure 5F, right),
Bcl6 expression was largely insensitive to these interventions,
with the exception of the PI3K inhibitor, LY294002 (Figure 5G).
These inhibitors were specific to the IL-2-mediated activation of
PI3K, as noted by a loss of p-S6 expression (Figure S4B, right)
and intact p-STAT5 expression (Figure S4B, left). These data
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Figure 4. Calcium and NFAT Signaling Promote Tfh Cell Function
(A) NFAT gene signature in Tfh and Th1 cells at 8 dpi. Highlighted transcripts are associated with NFAT signaling independent of cofactors.
(B) Calcium influx as assessed by the ratio of Fura-4 to Fura-Red in Tfh (black line) and Th1 (gray line) cells.
(C) Amnis Imagestream survey of nuclear NFAT in PSGL-1lo and PSGL-1hi cells as determined by the similarity dilate algorithm (Volk et al., 2014), with an increase
associated with nuclear NFAT.
(D) Graph of similarity dilate in PSGL-1lo (solid bars) and PSGL-1hi (gray bars) cells in unstimulated conditions, or after stimulation with ionomycin with or without
cyclosporine A (CsA) treatment.
(E) Amnis Imagestream images of ionomycin-treated Tfh cells and Th1 cells.
(F) IFN-g and IL-21 staining of Ly6cloCXCR5hi Tfh cells with or without CsA or rapamycin (RAPA) treatment.
(G) Results from (F) based on cytokine amounts expressed in untreated samples (percent of maximum). Abbreviations are as follows: DP, Tfh cells staining for
both IL-21 and IFN-g; SP, Tfh cells staining for IFN-g alone.
Results are representative of two independent experiments with three to five animals per experiment (B–G). +SEM (D and G). One-way ANOVA with multiple
comparisons (D and G). *p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001. Please see Figures S3 and S4 and Table S4.suggest that Bcl6 expression is independent of Akt and mTOR
signals, whereas cells expressing Blimp-1 are enriched in
mTOR activity, with Akt and mTOR signals necessary to induce
expression of the latter transcription factor.
mTOR Alters the Balance of Tfh versus Th1 Cell
Differentiation
mTOR is necessary for Th1 cell subset differentiation (Delgoffe
et al., 2009); however, its role in Tfh cell development is unclear.
To this end, we retrovirally transduced constructs containing
an mTOR small-hairpin RNA (shRNA) or control vector into
CD4+Stg+ T cells (Araki et al., 2009), followed by their transfer
into wild-type recipients and assessment of Tfh and Th1 cell
percentages at 8 dpi with LCMV. To validate the efficacy of
this vector, we confirmed that its transduction led to a reduction
in cell size and CD98 expression (Figures 6A and 6B; Rao et al.,
2010). We next queried the effect of mTOR silencing on Tfh and
Th1 cell development in vivo. Compared to cells bearing the
control vector, percentages and numbers of Th1 cells were sig-nificantly reduced after mTOR silencing (Figures 6C and S5B,
respectively), with a reduction in T-bet expression (Figure 6D).
The effects on Tfh cells were more variable, however, with an in-
crease in their percentage (Figure 6C) albeit without a significant
change in their numbers (Figure S5B) and a minimal reduction in
Bcl6 expression in transduced cells (Figure 6E).
We next assessed the ability of mTOR-deficient T cells to drive
GC B cell formation. OT-II TCR transgenic animals are unable to
promote GC responses upon LCMV challenge (Figure S5C;
Marshall et al., 2015), sowe used this system to adoptively trans-
fer transduced Stg+ T cells to promote B cell responses. We
transferred 7,000 sorted control or mTOR shRNA transduced
Stg+ T cells into these mice; the latter were equally capable
in promoting GC B cell differentiation compared to animals
receiving control-transduced cells (Figures S5D and S5E).
We also found, through testing one of the cohorts, that recipients
of either condition were equally capable in helping B cells
promote pathogen-specific antibody responses compared to
infected transgenic mice without receipt of transferred cellsImmunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc. 695
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Figure 5. Signaling via PI3K, Akt, and mTOR Promotes Th1 Cell Differentiation at the Expense of that of Tfh Cells
(A) Transcripts of transcription factors that are upregulated or downregulated in Tfh and Th1 cells.
(B) Blimp-1 YFP+ and Blimp-1 YFP cells gated on Ly6cloPSGL-1lo Tfh cells and Ly6cloPSGL-1lo Th1 cells (left). Percentages of Tfh cells and Th1 cells that make
up the Blimp-1 YFPlo and YFPhi gates at 8 dpi (right).
(C and D) FSC-A (C) and CD98 (D) expression in Blimp-1 YFPlo and YFPhi cells at 5 dpi.
(E) p-S6 expression compared to Blimp-1 YFP expression for CD4+ T cells cultured in vitro with 1.0 mMCD3, 1.0 mMCD28, and 10 nM IL-2 (left). p-S6 expression
in the same culture conditions, without or with inhibitors to PI3K (LY294002, LY, 25 mM), Akt (AktI, 1 mM), or mTOR (RAPA, 100 nM).
(F) Blimp-1 YFP expression in CD4+ T cells after stimulation with varying concentrations of CD3 andCD28 (both equal in concentration from 0 to 1.0 mM)without or
with added IL-2 (0–100 ng/ml) (left). Blimp-1 YFP expression in CD4+ T cells using the culture conditions as in (E) (right).
(G) Bcl6 expression in CD4+ T cells cultured in vitro with 1.0 mMCD3, 1.0 mMCD28, and 10 ng/ml IL-2, without or with addition of inhibitors to PI3K, Akt, or mTOR,
as in (E). Filled gray histogram denotes naive CD4+ T cells.
Representative of two independent experiments with five animals per experiment (B–D) or two independent experiments (E–G). +SEM (B–E). Two-way ANOVA
with multiple comparisons (B). Student’s unpaired t test (C and D). ****p% 0.0001. Please see Table S5.(Figure S5F), consistent with the dispensability of mTOR
signaling in Tfh cell function.
Because mTORc1 and mTORc2 have been shown to promote
different T cell subsets, with the requirement of mTORc1 for Th1
and Th17 cells (Delgoffe et al., 2009) and mTORc2 for Th2 cells
(Lee et al., 2010), we used shRNA vectors targeted against the
Raptor (mTORc1) and Rictor (mTORc2) complexes to determine
the roles of mTORc1 and mTORc2 in Th1 versus Tfh cell devel-
opment. Raptor silencing, similar to that of total mTOR, induced
Tfh cell differentiation at the expense of that of Th1 cells with
reduction in T-bet expression (Figures 6F, 6G, and S5G). How-
ever, Rictor silencing had minimal effects on Tfh cell develop-
ment, while promoting that of Th1 cells, albeit without a signifi-
cant effect on T-bet expression. These findings suggest that
mTORc1 suppresses Tfh cell development and induces that of
Th1 cells, thereby recapitulating total mTOR silencing. However,
mTORc2 might suppress Th1 cell development, enabling prefer-
ential differentiation of Tfh cells.
Given the finding that mTOR directs the balance of Tfh versus
Th1 cell differentiation toward the latter, we wondered whether696 Immunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc.c-Myc, which operates downstream of mTOR signaling to facili-
tate a glycolytic program in T cells (Wang et al., 2011), could deter
Tfh cell differentiation. We confirmed that TCR-dependent c-Myc
expression was dependent on mTOR in vitro (Figure 6H). Con-
sistent with this finding, c-Myc expression was significantly in-
creased in Th1 cells compared to Tfh cells (Figure 6I), and ectopic
expression of a constitutively active c-Myc was sufficient to pro-
moteTh1cell differentiation andmarkers associatedwithanabolic
metabolism compared to that of Tfh cells (Figure 6J; Wang and
Green, 2012). Thus, mTORc1 and c-Myc signaling are important
promoters of Th1 cell differentiation over that of Tfh cells.
IL-2 Signals via mTOR to Regulate Th1 versus Tfh Cell
Differentiation
Given the role of mTOR signaling in promoting Th1 cell differen-
tiation over that of Tfh cells, we next investigated its upstream
driver. IL-2 was a good candidate, given its signaling via
STAT5 and mTOR that promotes the Th1 cell fate (Brennan
et al., 1997; Johnston et al., 2012) and given our finding that
Blimp-1hi Th1 cells were enriched in mTOR activity, with IL-2
A B
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Figure 6. mTOR Alters the Balance of Tfh versus Th1 Cell Differentiation
(A and B) FSC-A and CD98 expression of total Stg+ T cells, transduced with an mTOR small-hairpin RNA (shRNA) or an empty control vector, 8 dpi after LCMV
infection.
(C) Percentages of Ly6chiPSGL-1hi Th1 and Ly6cloPSGL-1lo Tfh cells, as gated on CD4+CD44hiStg+ cells.
(D and E) T-bet (D) and Bcl6 (E) expression in total Stg+ transduced T cells.
(F) Percentages of Ly6chiPSGL-1hi Th1 and Ly6cloPSGL-1lo Tfh cells, as gated on CD4+CD44hiStg+ cells.
(G) T-bet expression in total Stg+ transduced T cells.
(H) MFI of activated c-Myc after stimulation of Stg+ cells with GP66 in the presence or absence of rapamycin (RAPA).
(I) c-Myc expression in Tfh and Th1 cells at 8 dpi.
(J) Control or constitutively active (CA)-c-Myc transduced Stg+ T cells gated on Tfh and Th1 cells.
Black and red lines in (A), (B), (D), and (E) represent gating on control and mTOR shRNA transduced Stg+ T cells, respectively, with dashed lines denoting naive
CD4+ T cells. Black, blue, and red lines in (G) represent gating on control, Raptor, and Rictor shRNA transduced Stg+ T cells, respectively, with filled gray
histograms denoting naive CD4+ T cells. Results are representative of two to four independent experiments with four to five animals per condition per
experiment. +SEM (A, B, D, E, G–I). Student’s unpaired t test (A–E, I, and J). One-way ANOVA with multiple comparisons (F–H). *p% 0.05, **p% 0.01, ***p%
0.001, ****p% 0.0001. Please see Figure S5.
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Figure 7. mTOR Signaling Is Downstream of that of CD25
(A) CD25 expression in Stg+Blimp-1 YFPhi and YFPlo cells at 5 dpi.
(B) p-S6 expression in wild-type CD4+ T cells after stimulation with a range of aCD3 and CD28 concentrations (0–1 mg/ml) cultured without or with a range of IL-2
amounts (0–100 ng/ml). LY294002, AktI, and RAPA, inhibiting signaling via PI3K, Akt, and mTOR, respectively, were used at concentrations as in Figure 5, and
tested in conditions with 1 mg/ml aCD3 and 1 mg/ml CD28 and 10 ng/ml IL-2.
(C) p-S6 staining in Stg+CD4+CD44+ cells at 5 dpi.
(D) Single- and double-transduced Stg+ cells gated on Ly6cloPSGL-1lo Tfh and Ly6chiPSGL-1hi Th1 cells and normalized to their control vectors (LMP, MIGR1-
Thy1.1, LMP and MIGR1-Thy1.1; dotted line).
(E) T-bet and Bcl6 expression in single- and double-transduced cells normalized to the mean of their control vectors (dotted line).
Blue and red lines in (C) represent gating on Tfh and Th1 cells, respectively, with the filled histogram denoting naive CD4+ T cells. Results are representative of two
independent experimentswith five animals per condition per experiment (A–E). +SEM (C and E). Student’s unpaired t test (A andC); one-way ANOVAwithmultiple
comparisons (D, E). *p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001. Please see Figure S6.induction of Blimp-1 dependent on the latter, along with PI3K
and Akt signaling (Figures 5F and 5G). Whereas Blimp-1 YFP+
cells, as expected, were CD25hi after LCMV challenge (Figures
7A and S6A), we also detected expression of CD25 in Blimp-1
YFPlo cells in vitro, suggesting that its upregulation can precede
that of Blimp-1 (Figure S6B, left). Accordingly, we observed that
CD25hi Blimp-1 YFPlo cells, as well as their CD25hiYFPhi counter-
parts, had increased p-S6 (Figure S6B, right), finding a linear
relationship between its phosphorylation and increasing con-
centrations of IL-2 (Figure 7B). Increasing doses of IL-2 also
upregulated CD25 expression (Figure S6C), yet suppression of
Akt and mTOR signaling by AktI and RAPA, respectively, while
inhibiting p-S6 expression (Figure 7B), did not greatly alter that
of CD25 (Figure S6C), suggesting that p-S6 was not directly
responsible for its expression.
STAT5 signaling promotes upregulation of CD25, which not
only feeds forward to enhance p-STAT5 activity, but also pro-
motes augmented PI3K and Ras signaling (Brennan et al.,
1997). This indicated that IL-2 could promote Th1 versus Tfh
cell development by regulating mTOR activity. To test this
idea, we silenced CD25 expression on Stg+ cells via an shRNA,
which markedly reduced p-S6 and p-Rb staining in total Stg+
cells in vivo at 5 dpi (Figures 7C and S6D). We then used the
CD25 shRNA vector without, or in combination with, a vector ex-
pressing constitutively active myristolated-Akt (myr-Akt) (Aguilar
et al., 2007). As previously reported, silencing of CD25 reduced
the development of Th1 cells and T-bet expression at 5 dpi, while698 Immunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc.promoting that of Tfh cells (Figures 7D, S6E, and S6F) and Bcl6
(Figure 7E) (Johnston et al., 2012). Conversely, overexpression of
myr-Akt promoted Th1 cell differentiation and T-bet upregulation
at the expense of Tfh cells and Bcl6 expression (Figures 7D, 7E,
S6E, and S6F). In double-transduced cells, myr-Akt restored Th1
cells to wild-type amounts when CD25 signaling was sup-
pressed, suggesting that Akt activity could circumvent the
need for IL-2 signaling during such differentiation (Figures 7D,
S6E, and S6F). Similarly, T-bet and Bcl6 were restored by myr-
Akt (Figure 7E). Thus, IL-2 appears to represent a central rheo-
stat, signaling via PI3K, Akt, and mTOR to regulate Tfh and
Th1 cell differentiation in vivo.
DISCUSSION
In tune with their differing functions and migratory patterns, we
found that Tfh cells utilized distinct signaling pathways and
differed in their metabolic requirements compared to Th1 cells.
The former were less proliferative and displayed an inability to
maximally engage aerobic glycolysis, probably because of
reduced mTOR activity in these cells, compared to Th1 cells.
In line with these data, IL-2 activation of Akt and mTOR was
necessary for induction of the Th1 cell transcription factor
Blimp-1, but not the Tfh cell transcription factor Bcl6. Further-
more, the preferential differentiation of Tfh cell differentiation
that occurred in the context of CD25 silencing was reversed by
hyper-activation of Akt. Therefore, IL-2 is likely to be epistatic
to mTOR activity for commitment to the Th1 cell lineage, func-
tioning as a critical rheostat in the regulation of the reciprocal dif-
ferentiation and metabolism of Th1 versus Tfh cells. Yet, despite
reductions in PI3K, Akt, and mTOR, Tfh cells retained the ability
to flux calcium and demonstrated enhanced basal and activa-
tion-induced nuclear translocation of the transcription factor
NFATc1. NFAT activity, but not signaling via mTOR, was func-
tionally required downstream of the TCR for production of the
canonical Tfh cytokine, IL-21.
Nutrient uptake is also a major contributor to T cell subset dif-
ferentiation and function. Th1, Th17, and Th2 cells all require
mTOR and glucose for their development, whereas Treg cells
require neither mTOR nor glucose, instead utilizing exogenous
fatty acids (Delgoffe et al., 2009; Michalek et al., 2011). Our find-
ings that Tfh cells have reduced mitochondrial function and
glucose uptake, as well as reducedmaximal respiratory capacity
and extracellular acidification compared to Th1 cells, are indica-
tive of a relatively quiescent metabolic state. Because Tfh cells
are less reliant on high amounts of glucose and mTOR activity
for their function, these cells share some of the same molecular
and metabolic underpinnings as Treg cells. Indeed, their re-
duced IL-2-driven glycolysis program, negatively regulated by
Bcl6 (Oestreich et al., 2014), has metabolic consequences for
these cells in vivo. Despite their reduced metabolic capacity,
however, we showed that Tfh cells require both glucose and
mitochondrial ATPase for cytokine secretion, suggesting that
they uptake glucose as well as utilize oxidative phosphorylation
to maintain function.
Whereas STAT5-induced Blimp-1 expression is critical for
regulating the balance between Th1 and Tfh cell fates, our data
indicated that Blimp-1 expression is dependent on Akt and
mTOR signaling. One potential explanation for the requirement
of STAT5 in the induction of Blimp-1 is its requirement in the up-
regulation of the high-affinity IL-2 receptor alpha chain, CD25,
which stabilizes IL-2 and IL-2R interactions, thereby potentiating
IL-2 signaling (Smith, 1988; Villarino et al., 2007;Waldmann et al.,
2001). Indeed, CD25 expression was virtually absent in the CD4+
T cells lacking STAT5 (Johnston et al., 2012). In addition to acti-
vating STAT5, IL-2 activates both Ras and PI3K. The IL-2Rb
cytoplasmic tail induces activation of all of these pathways:
upon IL-2 ligation, IL-2Rb phosphorylates STAT5 at IL-2Rb510
and PI3K at IL-2Rb392, and it stimulates Ras signaling via IL-
2Rb338 phosphorylation of Shc (Brennan et al., 1997). Therefore,
STAT5-induced CD25 upregulation probably serves not only
to positively feed back on STAT5 activity, but also to enhance
IL-2-induced PI3K and Ras signaling. Our findings show that
ectopic expression of a constitutively active Akt (myr-Akt) re-
stored Th1 cell differentiation in the absence of high-affinity IL-
2 signaling via CD25. These data argue that IL-2 activation of
Akt and mTOR signaling is critical in orchestrating the reciprocal
differentiation of Th1 and Tfh cell lineages and demonstrate that
IL-2 conducts two signaling arms that are important for T cell dif-
ferentiation, via STAT5 and PI3K (Figure S6G, red Th1 cell). In line
with this hypothesis, Treg cells, which expand in the absence of
mTOR (Delgoffe et al., 2009) and which suppressor function is
defunct with ablation of the phosphatase PTEN that suppresses
PI3K function (Huynh et al., 2015; Shrestha et al., 2015), require
IL-2Rb activation of STAT5 formaintenance of FoxP3 expression
(Burchill et al., 2007; Yao et al., 2007). Therefore, Treg cells haveintact IL-2 signaling via STAT5, whereas their signaling via PI3K
is attenuated by PTEN (Figure S6G, green Treg cell). We found
that IL-2 signaling in Tfh cells, unlike Treg and Th1 cells, was
impaired in both pathways, which explains their reduction in
CD25 expression and upregulation of Bcl6 via STAT3 binding,
as well as their reduction in mTOR signaling and anabolic meta-
bolism (Figure S6G, blue Tfh cell).
How do Tfh cells suppress CD25 signaling, and subsequently
that of Akt and mTOR, during their differentiation? Expression
of CD25 and the canonical Tfh cell marker CXCR5 is mutually
exclusive early after LCMV Armstrong and Listeria monocyto-
genes infections (Johnston et al., 2012; Pepper et al., 2011).
Tfh cells also are unaffected by CD25 ablation, unlike Th1 cells,
suggesting that this cytokine is not important for Tfh cell devel-
opment. It remains to be tested whether TCR:MHCII-peptide
dwell-time interactions (Tubo et al., 2013) or ICOS signaling
can directly suppress CD25 upregulation in Tfh cells, thus pro-
tecting them from high-affinity IL-2 signaling and subsequent
Akt and mTOR activation. ICOS signaling activates the PI3K
and Akt pathway and is critical for the induction of nascent Tfh
cells, but subsequent suppression of this pathwaywith induction
of FOXO1 drives development of mature Tfh cells (Stone et al.,
2015). Thus, it will be important to understand how the quality
of PI3K, Akt, and mTOR signaling downstream of the IL-2 re-
ceptor and of ICOS promotes the specification of Th1 versus
Tfh cells early after T cell activation. We have also shown that
STAT3 protects against the effects of STAT5 regulation at the
Bcl6 locus. It might do the same at the CD25 locus, as we found
that STAT3-deficient Tfh cells have an increase in CD25 ex-
pression (Ray et al., 2014). These mutant Tfh cells, which have
characteristics of Th1 cells, also have patterns of gene expres-
sion associated with enhancement of c-Myc, NF-kB, and E2f1
cellular pathways, according to IPA analysis (Ray et al., 2014).
Thus, competing cytokine signals appear to shield Tfh cells
from IL-2 signaling, aiding their differentiation.
The study of T cell subset signaling and metabolism has impli-
cations for creating therapeutics for infectious and autoimmune
diseases. Targeting the mTOR pathway in T cells would prefer-
entially promote Tfh cell differentiation while suppressing Th1
cell differentiation, as we have shown. However, global treat-
ment with metabolic inhibitors, such as rapamycin, is likely to
affect other cell types that are essential for Tfh cell formation,
e.g., dendritic cells or GC B cells. Thus, although targeting meta-
bolic pathways might be useful in design of vaccination strate-
gies or therapy of autoimmunity, the effects of these interven-
tions on differential regulation of CD4+ T cell fate need careful
consideration.EXPERIMENTAL PROCEDURES
Mice and LCMV Infection
Mice were housed in specific-pathogen-free conditions at the Yale School
of Medicine. C57BL/6 (B6) mice were purchased from the National Cancer
Institute, with SMARTA Tg (Tg(TcrLCMV)1Aox) from Hans Hengartner at the
University of Zu¨rich in Switzerland, Blimp-1 YFP animals (B6.Cg-Tg(Prdm1-
EYFP)1Mnz/J) from Michel Nussenzweig at New York University, and OT-II
Tg mice from Jackson Laboratories. All were used at 6–8 weeks of age. The
Institutional Animal Care and Use Committee of Yale University approved all
procedures involving mice. They were infected with LCMV Armstrong by i.p.
injection of 2 3 105 PFU per mouse.Immunity 43, 690–702, October 20, 2015 ª2015 Elsevier Inc. 699
PI3K, Akt, mTOR, NFAT, Glucose, and Oxidative Phosphorylation
Inhibitor In Vitro Treatments
Inhibitors for PI3K (LY294002, 25 mM), AKT (AktI, 1 mM),mTOR (RAPA, 100 nM),
andNFAT (CsA, 1 mM)were used to treat Blimp-1 YFP cells for 2 dayswith vary-
ing doses of IL-2 (0–100 ng/ml) and TCR signaling (aCD3 and aCD28 at match-
ing concentrations from 0–1 mM). For cytokine staining, RAPA was used at
200 nM, CsA at 1 mM, 2-DG at 50 mM, and oligomycin (ATPase inhibitor,
0.5 mM), added 15 min before stimulation of cells with GP61–80 peptide.
Seahorse Extracellular Flux Assay
Seahorse analysis experiments were performed as previously described (He-
nao-Mejia et al., 2013) and discussed in brief in the Supplemental Experi-
mental Procedures.
Calcium Flux Assay
D8Stg CD4+ T cells were stained formarkers of Tfh (CD4+Thy1.1+Ly6cloPSGL-
1lo) or Th1 (CD4+Thy1.1+Ly6chiPSGL-1hi) cells on ice for 20 min and then these
cells were loaded with a mixture of Fura-4AM (1 mg/ml) and Fura-Red (2 mg/ml)
(Life Technologies) at 37C for 10 min. After washing twice with PBS, cell pel-
lets were suspendedwith RPMI containing 10%FBS. Intracellular calciumwas
analyzed by flow cytometry for 30 s to acquire baseline levels followed by cell
stimulation with ionomycin. Calcium influx was determined as the ratio be-
tween Fura-Red and Fura-4AM fluorescence intensity.
Retroviral Transduction and Cell Transfer
For retroviral transduction, 1 mg of LMP, MIGR1-GFP, MIGR1-Thy1.1, mTOR
shRNA, Myr-Akt, and/or CD25 shRNA vector with 0.5 mg of EcoHelp plasmid
were used to transfect HEK293T viral packaging cells using X-tremeGENE 9
DNA transfection reagent (Roche) overnight. The media was then replaced
and virus was grown for another 24 hr. 6 3 106 splenocytes were activated
for 24 hr using GP66 peptide stimulation and spin transduced with the superna-
tant of the transfection with polybrene. Post-transduction, 13 105 Stg+ T cells
were transferred via retro-orbital injection into infected B6 recipients that were
subsequently infected with LCMV Armstrong. For B cell activity analysis, Stg
T cells transduced with mTOR shRNA or control vector were cultured for a
period of 24 hr before sorting. These cells were then sorted on GFP positivity
and transferred at 7,000GFP+ Stg cells/mouse into OT-II mice that were subse-
quently infected with LCMV. Thesemice were sacrificed at 8 dpi to assess their
B cell responses to LCMV. For nontransduced cells, 23 105 wild-type or Blimp-
1 YFP+ naive STg+ CD4+ T cells were transferred via retro-orbital injection into
wild-type mice. At 12–24 hr later, mice were infected with LCMV Armstrong by
i.p. injection. At 3, 5, and 8 dpi, depending on the experiment, spleenswere har-
vested for flow cytometry for phenotypic analysis.
Statistics
Datawere analyzedasdescribed in theSupplemental Experimental Procedures.
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